VEA
KDNY

Virtus ETF Advisers’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Virtus ETF Advisers’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,052
Closed -$93.8K – 490
2023
Q1 		$93.8K Sell
4,052
-1,558
-28% -$37.1K 0.05% 350
2022
Q4 		$147K Sell
5,610
-880
-14% -$19.5K 0.08% 350
2022
Q3 		$128K Buy
6,490
+49
+0.8% +$983 0.05% 384
2022
Q2 		$113K Sell
6,441
-4,095
-39% -$64.3K 0.04% 401
2022
Q1 		$172K Sell
10,536
-622
-6% -$8.46K 0.08% 211
2021
Q4 		$182K Sell
11,158
-1,474
-12% -$21K 0.07% 244
2021
Q3 		$161K Sell
12,632
-667
-5% -$8.78K 0.07% 325
2021
Q2 		$188K Buy
+13,299
New +$213K 0.08% 373
2018
Q4 		– Sell
-12,293
Closed -$452K – 402
2018
Q3 		$452K Sell
12,293
-8,787
-42% -$282K 0.05% 137
2018
Q2 		$738K Buy
21,080
+2,600
+14% +$99.7K 0.65% 78
2018
Q1 		$859K Buy
18,480
+9,933
+116% +$364K 0.75% 64
2017
Q4 		$321K Buy
8,547
+2,410
+39% +$105K 0.4% 114
2017
Q3 		$327K Buy
6,137
+561
+10% +$33.3K 0.04% 127
2017
Q2 		$318K Buy
5,576
+464
+9% +$23.3K 0.05% 110
2017
Q1 		$275K Buy
5,112
+490
+11% +$27.7K 0.05% 147
2016
Q4 		$263K Buy
4,622
+420
+10% +$25.4K 0.08% 127
2016
Q3 		$261K Hold
4,202
– – 0.13% 120
2016
Q2 		$238K Buy
4,202
+2,609
+164% +$159K 0.18% 106
2016
Q1 		$102K Buy
+1,593
New +$129K 0.14% 143

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Virtus ETF Advisers's KDNY Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 4,052 shares — an estimated $93.8K sold.

Virtus ETF Advisers first reported a position in KDNY in Q1 2016 and held it in 19 quarters. The position peaked at $859K in Q1 2018. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 4,052 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $93.8K.
  • Virtus ETF Advisers first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 19 quarters.
  • Virtus ETF Advisers's Chinook Therapeutics, Inc. Common Stock position peaked at $859K in Q1 2018.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.